From the Gut to the Lung: Evidence of Antifibrotic Activity of Endocrine Fibroblast Growth Factor 19

Robert D. Guzy,Seth Bollenbecker,Stefanie Krick

DOI: https://doi.org/10.1165/rcmb.2022-0057ED

IF: 7.748

2022-08-03

American Journal of Respiratory Cell and Molecular Biology

Abstract:Idiopathic pulmonary fibrosis (IPF) is the most common and most severe form of pulmonary fibrosis, a scarring disease of the lungs resulting in progressive lung stiffness and hypoxemia with a poor prognosis (1). Pulmonary fibrosis remains the most common indication for lung transplantation despite the emergence of antifibrotic medications. Both of the available antifibrotic medications used in IPF, pirfenidone and nintedanib, have been shown to include fibroblast growth factor (FGF) signaling pathways as their targets. FGFs comprise a family of 22 known growth factor ligands that act in an autocrine, paracrine, or endocrine manner to signal through four known FGF receptors (2). There is evidence that pirfenidone alters FGF2 expression in mouse lungs in response to bleomycin (3), a commonly used agent to induce pulmonary fibrosis in rodents. Nintedanib is a receptor tyrosine kinase inhibitor that primarily inhibits platelet-derived growth factor, vascular endothelial growth factor, and FGF receptors (4). While FGFs and their activated signaling pathways have been implicated in the pathogenesis of pulmonary fibrosis, their specific roles, as well as whether they act as pro or antifibrotic growth factors, remain topics of active investigation.

biochemistry & molecular biology,cell biology,respiratory system